Xiao Kaimin, Tang Ji, Yang Xinwei, Chen Hongmei, Liu Ping, He Rongxin, Xie Lihui, Chu Heling, Tang Yuping, Chen Li
Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of Neurology, People's Hospital of Ganxian District, Ganzhou, China.
Sci Rep. 2025 Aug 20;15(1):30666. doi: 10.1038/s41598-025-15764-5.
Ischemic stroke is a major health concern, particularly in patients with type 2 diabetes mellitus (T2DM), who are at elevated risk. This study aimed to evaluate the prognostic impact of glibenclamide pretreatment on patients with acute ischemic stroke and T2DM. A total of 122 patients with acute ischemic stroke and T2DM were retrospectively analyzed. Based on medication history, patients were categorized into the glibenclamide group (group 1, n = 54) and the control group (group 2, n = 68). Stroke severity at admission was assessed using the National Institutes of Health Stroke Scale (NIHSS), and functional status was evaluated with the Barthel Index (BI) and modified Rankin Scale (mRS). Patients were followed for 3 months. At admission, group 1 demonstrated significantly better neurological function (lower NIHSS) and higher BI scores compared to group 2 (P < 0.05). At 3 months, mortality was 1.9% in group 1 and 5.9% in group 2, though this difference was not statistically significant (χ = 0.430, P = 0.512). Adverse events occurred in 7.4% and 10.3% of patients in groups 1 and 2, respectively (P > 0.05), with no drug-related deaths or serious safety concerns. The incidence of hemorrhagic transformation also showed no significant difference (P > 0.05). However, group 1 showed significantly better functional outcomes at 3 months, with higher BI scores and lower mRS scores (P < 0.05), suggesting improved independence and neurological recovery. Glibenclamide pretreatment in patients with acute ischemic stroke and T2DM may confer clinical benefits by reducing stroke severity and enhancing post-stroke functional outcomes, without increasing adverse events.
缺血性中风是一个主要的健康问题，尤其是在2型糖尿病（T2DM）患者中，这类患者风险更高。本研究旨在评估格列本脲预处理对急性缺血性中风合并T2DM患者预后的影响。对122例急性缺血性中风合并T2DM患者进行了回顾性分析。根据用药史，将患者分为格列本脲组（第1组，n = 54）和对照组（第2组，n = 68）。入院时使用美国国立卫生研究院卒中量表（NIHSS）评估中风严重程度，并用巴氏指数（BI）和改良Rankin量表（mRS）评估功能状态。对患者进行了3个月的随访。入院时，第1组的神经功能明显优于第2组（NIHSS更低），BI评分更高（P < 0.05）。3个月时，第1组的死亡率为1.9%，第2组为5.9%，尽管这一差异无统计学意义（χ = 0.430，P = 0.512）。第1组和第2组分别有7.4%和10.3%的患者发生不良事件（P > 0.05），无药物相关死亡或严重安全问题。出血性转化的发生率也无显著差异（P > 0.05）。然而，第1组在3个月时的功能结局明显更好，BI评分更高，mRS评分更低（P < 0.05），表明独立性和神经功能恢复有所改善。急性缺血性中风合并T2DM患者的格列本脲预处理可能通过降低中风严重程度和改善中风后功能结局而带来临床益处，且不增加不良事件。
